Vancouver, Canada, 1 December 2015 – Results from the Perceptions of Control (POC) study showed that people with type 2 diabetes uncontrolled on basal insulin were reluctant to intensify insulin therapy due to concerns such as medication side effects, perceptions of getting sicker and not wanting to add more injections. Physicians’ concerns around insulin intensification included a lack of patient agreement to intensify insulin therapy, hypoglycaemia and patients’ cognitive status.1 Findings from the Perceptions of Control study which evaluated the perceptions of diabetes control amongst patients and physicians were presented today at the World Diabetes Congress of the International Diabetes Federation (IDF). read more
Victoza® (liraglutide) provides greater glycaemic control than SGLT-2 inhibitors
Vancouver, Canada, 1 December 2015 – New findings from a network meta-analysis show that treatment with Victoza® (liraglutide) provides a greater HbA1c reduction and an improved likelihood of reaching glycaemic goals compared to sodium-glucose co-transporter 2 (SGLT-2) inhibitors in people with type 2 diabetes who are inadequately controlled with metformin alone or in combination with sulfonylurea, dipeptidyl peptidase-4 (DPP-4) inhibitors or thiazolidinedione.1 Findings were presented today at the World Diabetes Congress of the International Diabetes Federation (IDF) in Vancouver, Canada. read more
New Data Show Lilly’s Once-Weekly Trulicity® (dulaglutide) is Effective as Add-on Treatment to Sulfonylurea
Trulicity 1.5 mg Demonstrates Superior Efficacy in AWARD-8 Trial
INDIANAPOLIS, Dec. 1, 2015 /PRNewswire/ — New data from a completed Phase 3 trial show Trulicity® (dulaglutide) 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea alone in lowering hemoglobin A1c (A1C) from baseline after 24 weeks of treatment.1 Trulicity is Eli Lilly and Company’s (NYSE: LLY) once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes. These data, from the Trulicity AWARD-8 clinical trial, were presented for the first time today at the 2015 International Diabetes Federation (IDF) World Diabetes Congress in Vancouver, Canada. read more
Digital Temple Thermometer (DTT) by K-Jump Health Co., Ltd.: Recall – Inaccurate Temperature Display
Model No. KD-2201 manufactured by K-Jump Health Co., Ltd, featuring lot numbers S/N: 3612 through S/N: 3715, which were sold between October 2012 until the start of the recall in November 2015.
Some Digital Temple Thermometers contain a manufacturing problem causing the affected thermometers to display temperatures that are inaccurate and lower than actual body temperatures, which potentially may cause the user or caregiver of the user to delay or forego seeking appropriate care (generally an over-the-counter fever reduction medication) or receive more care than appropriate, when relying solely on the temperature display on the thermometer. read more
GE Completes Sale of Healthcare Financial Services Business
FAIRFIELD, Conn.–(BUSINESS WIRE)–GE (NYSE:GE) announced today that it has completed the previously announced sale of its GE Capital, Healthcare Financial Services (HFS) U.S. lending business, representing aggregate ending net investment (ENI) of approximately $8.3 billion, to Capital One. read more
GHO Capital Acquires Quotient Clinical
–(BUSINESS WIRE)–GHO Capital, the European specialist healthcare investor, today announces the acquisition of Quotient Clinical (Quotient or the Company), a provider of outsourced, early-stage drug development services to the pharmaceutical industry.
Headquartered in the UK and employing over 280 professionals, Quotient Clinical enables pharmaceutical and biotechnology customers to improve research and development productivity and accelerate drug development timelines. read more
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, granted equity awards on November 30, 2015, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to four individuals hired by Sarepta in November 2015. The equity awards were approved in accordanc
e with NASDAQ Listing Rule 5635(c)(4). read more
Takeda Welcomes the Publication of New National Institute for Health and Care Excellence (NICE) Guidelines on the Management of Type 2 Diabetes in Adults
Takeda UK Managing Director Adam Zaeske, comments on the publication of new NICE Guidelines on the management of Type 2 diabetes in adults (NG28).
“The escalating burden of Type 2 diabetes is of concern to everyone working to improve health outcomes for patients so we need to work together to help manage the condition,” stated Takeda UK Managing Director Adam Zaeske, on the publication of new NICE Guidelines on the management of Type 2 diabetes in adults (NG28).
Takeda has a heritage of discovery and commitment to advancing patient care in diabetes, and as such is pleased to support the new guidelines from NICE.
“With close to 10 million people in the UK at risk of developing Type 2 diabetes, there is an urgent need for sustained and strategic action to reduce the ever-increasing burden of Type 2 diabetes on the NHS, as well as the huge impact the condition can have on patients and their families.
“Diabetes is reaching epidemic proportions across much of the developed world, and is one of the most important healthcare challenges we face,” he added.
In the UK, diabetes affects some 3.2 million people, around 6% of the population, and costs the country an estimated £23.7 billion per annum.
Fabre-Kramer Looks Forward to FDA’s Decision on Gepirone ER for the Treatment of Major Depressive Disorder
SILVER SPRING, Md. and HOUSTON, Dec. 2, 2015 /PRNewswire/ — Fabre-Kramer Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) completed its review of gepirone ER for the treatment of major depressive disorder (MDD) and that the input from the committee will be considered by Dr. John Jenkins, the Director of the Office of New Drugs at the Center for Drug Evaluation and Research at FDA. Fabre-Kramer remains cautiously optimistic based on the discussion at the PDAC today. read more
Accelovance, Inc. Continues Geographic and Service Expansion with Acquisition of Clinquest, Inc. & BV
ROCKVILLE, Md. and BOSTON and AMSTERDAM, Dec. 2, 2015 /PRNewswire-USNewswire/ — Accelovance, Inc. (Accelovance), a global contract research organization (CRO) focusing in oncology, vaccines, and general medicine clinical research; today announced it has acquired Clinquest, Inc. (US) and Clinquest Services BV (the Netherlands) (Clinquest) from Clinquest Group BV. With offices in ‘s-Hertogenbosch, the Netherlands, and Boston, MA; Clinquest provides clinical research, data management/biostatistics, medical information, and pharmacovigilance services to the pharmaceutical and biotech industries. The acquisition continues the expansion of Accelovance’s existing US and European footprint while also providing the company with extensive expertise in pharmacovigilance services. read more